On the question of the treatment of chronic hepatitis C with HIV co-infection in patients with lymphoma
| Autor: | O V Mukhin, M V Tumanova, N I Stuklov, A V Chistyakova, E P Shtyrlina, M G Dubnitskaya, A V Pivnik |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Cancer Research
medicine.medical_specialty Cirrhosis Hepatitis C virus Population aids-related lymphomas medicine.disease_cause lcsh:RC254-282 Gastroenterology AIDS-related lymphoma Internal medicine medicine education education.field_of_study Hematology business.industry virus diseases lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Lymphoma Oncology Hepatocellular carcinoma chronic hepatitis c business Viral hepatitis hiv-coinfected patients |
| Zdroj: | Современная онкология, Vol 18, Iss 5, Pp 36-38 (2016) |
| ISSN: | 1815-1434 |
| DOI: | 10.26442/1815-1434_2016.5.36-38 |
| Popis: | Due to the use of HAART, the efficacy of the treatment of AIDS-related lymphomas and indicators of survival in patients are close to those in the general population of lymphoma patients without HIV. According to the data of department of hematology and secondary immunodeficient conditions of Moscow Clinical Research Center 176 patients with lymphomas associated with HIV were treated for the period 2011-2015. The percentage of patients with hepatitis virus co-infection (C, B or C+B co-infection) is nearly 50%. Co-infection viral hepatitis, particularly hepatitis C virus (HCV) causes certain difficulties that, such as a more rapid progression of liver failure (development of cirrhosis and/or hepatocellular carcinoma). Use of new highly active drugs in viral infections treatment allows to increase the efficacy of the treatment of lymphomas associated with HIV and viral hepatitis. The treatment of HCV in HIV co-infected patients must be prioritized due to the rapid progression of liver failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|